Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4750040
Max Phase: Preclinical
Molecular Formula: C25H26N4O7
Molecular Weight: 494.50
Molecule Type: Unknown
Associated Items:
ID: ALA4750040
Max Phase: Preclinical
Molecular Formula: C25H26N4O7
Molecular Weight: 494.50
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC1=C(C(=O)Nc2ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc2)C(c2ccc(C)cc2)NC(=O)N1
Standard InChI: InChI=1S/C25H26N4O7/c1-13-3-5-15(6-4-13)21-20(14(2)26-25(36)29-21)23(33)27-17-9-7-16(8-10-17)22(32)28-18(24(34)35)11-12-19(30)31/h3-10,18,21H,11-12H2,1-2H3,(H,27,33)(H,28,32)(H,30,31)(H,34,35)(H2,26,29,36)
Standard InChI Key: BCDBSYJBKQOZRH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 494.50 | Molecular Weight (Monoisotopic): 494.1801 | AlogP: 2.31 | #Rotatable Bonds: 9 |
Polar Surface Area: 173.93 | Molecular Species: ACID | HBA: 5 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.19 | CX Basic pKa: | CX LogP: 1.22 | CX LogD: -5.43 |
Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.31 | Np Likeness Score: -0.76 |
1. Bibi M,Qureshi NA,Sadiq A,Farooq U,Hassan A,Shaheen N,Asghar I,Umer D,Ullah A,Khan FA,Salman M,Bibi A,Rashid U. (2021) Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase., 210 [PMID:33187806] [10.1016/j.ejmech.2020.112986] |
Source(1):